George Simeon
SEC-identified person · CIK 1595117 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Nkarta, Inc. NKTX | Director | filed 2020–2026 |
| Design Therapeutics, Inc. DSGN | Director | filed 2021–2026 |
| Crispr Therapeutics AG CRSP | Director | filed 2016–2026 |
| Odyssey Therapeutics, Inc. ODTX | Officer | filed 2026–2026 |
| Avalyn Pharma Inc. AVLN | Officer | filed 2026–2026 |
| Zenas Biopharma, Inc. ZBIO | Officer | filed 2024–2025 |
| Effector Therapeutics, Inc. LWAC | Officer | filed 2021–2023 |
| Arcellx, Inc. ACLX | Officer | filed 2022–2023 |
| Turning Point Therapeutics, Inc. TPTX | Director | filed 2019–2022 |
| Principia Biopharma Inc. PRNB | Director | filed 2018–2020 |
| HTG Molecular Diagnostics, INC HTGM | Director | filed 2015–2015 |
| Genocea Biosciences, INC. GNCA | Director | filed 2014–2014 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.